Last reviewed · How we verify
BACITRACIN ZINC
At a glance
| Generic name | BACITRACIN ZINC |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
Common side effects
Key clinical trials
- Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty (PHASE1)
- Nailbed Repair for Patients With Nailbed Injuries (NA)
- The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown (PHASE4)
- Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns (PHASE1)
- Impaired Risk Awareness During Intoxication in DUI Offenders (NA)
- Multi-omics Dissection of Gut Microbiome Engraftment During FMT (NA)
- The Effects of Post-Operative Interventions on Surgical Site Occurrences in AWR (NA)
- Comparison of Collagenase With Antibiotic Ointment of Minor Partial Thickness Burns (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BACITRACIN ZINC CI brief — competitive landscape report
- BACITRACIN ZINC updates RSS · CI watch RSS